^
    Back
    Association details:
    Biomarker:STRN-ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Thorac Cancer
    Title:

    Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report

    Published date:
    05/07/2021
    Excerpt:
    Here, we report a rare case of striatin (STRN)-ALK-positive NSCLC showing primary resistance to first-line therapy alectinib and limited clinical activity of crizotinib in the alectinib-resistant setting.
    DOI:
    10.1111/1759-7714.13983